V-VET1

About Genelux

Genelux is a clinical-stage biotech focused on developing oncolytic viral immunotherapies to treat cancer. Its mission is to leverage its proprietary CHOICE™ platform, built on the vaccinia virus backbone, to create therapies that deliver a full complement of tumor neoantigens and stimulate a potent, personalized immune response. The company's strategy centers on advancing its lead candidate, Olvi-Vec, through late-stage trials in ovarian cancer and other solid tumors, while pursuing strategic partnerships and leveraging in-house manufacturing capabilities to build a fully integrated therapeutics company.

Therapeutic Areas